Three newly published peer-reviewed papers are further expanding the extensive scientific evidence base of SightGlass Vision’s Diffusion Optics Technology (DOT 0.2) use for myopia management with children.
SightGlass Vision operates as a joint venture of CooperCompanies and EssilorLuxottica.
Its patent-protected technology has made its commercial debut in several markets, including China, the Netherlands, Israel, and Canada, as well as through preliminary market trials in other countries.
In a media release, Ms Marcella McParland, a qualified optometrist and SightGlass Vision’s vice president of Clinical, Medical & Professional Affairs, said: “Independently, these Open Access papers each deepen knowledge of our innovative technology among the global ophthalmology and optometry communities.
“Collectively, they are providing eyecare professionals with even more confidence in our approach and the impact that DOT lenses can have on children’s lives today and in the future.”
“Control of Myopia Using Diffusion Optics Spectacle Lenses: 4-Year Results of a Multicentre Randomised Controlled, Efficacy and Safety Study (CYPRESS)” (Laughton D, et al) appears in BMJ Open Ophthalmology.
The release said the study demonstrated that DOT 0.2 spectacle lenses were safe and effective at reducing myopia progression, significantly slowing eye growth, with additional benefit evident in the fourth year of wear.
In addition to supporting the hypothesis that a slight lowering of retinal contrast can slow the progression of myopia, the clinical trial is the first multi-centre study to demonstrate myopia control in an ethnically diverse population with children as young as age six.
This outcome in younger patients was noteworthy, due to their fast physiological and myopic eye growth, the release said.
Published in Ophthalmic & Physiological Optics, the journal of The College of Optometrists, “Visual Impact of Diffusion Optic Technology Lenses for Myopia Control” affirms that the SightGlass Vision mechanism provides a clinically equivalent visual experience to standard single vision lenses across key measures.
The study at six US sites was led by Professor James S. Wolffsohn, chief scientific officer for the International Myopia Institute and head of the Aston University School of Optometry.
“Prof Wolffsohn and his co-authors emphasised that DOT lenses provided a clinically equivalent visual experience to standard single vision lenses and did not compromise reading speed, critical print size, and near visual acuity; maintained normal head posture and contrast sensitivities; and demonstrated excellent high- and low-contrast visual acuities and stereopsis,” according to the release.
Written by noted vision scientists and researchers Drs Jay Neitz and Maureen Neitz, “Diffusion Optics Technology (DOT): A Myopia Control Spectacle Lens Based on Contrast Theory” presents an in-depth review of the science behind DOT’s innovative methodology.
Appearing in Translational Vision Science & Technology, the paper explores the fundamentals of contrast theory, how it compares to blur and defocus approaches, and the resulting implications for the design of optical interventions.
More reading
SightGlass Vision achieves FDA milestone for myopia spectacle lens
MiSight myopia control contact lenses now available in higher prescriptions
Rodenstock’s new myopia lens targets horizontal meridian
